2025
MR and CT Imaging of Temporal Lobe Encephalocele Associated Epilepsy: A Pictorial Review
De Jesus G, Nitz D, Damisah E, Mahajan A, Herlopian A, Vadivelu K, Bronen R. MR and CT Imaging of Temporal Lobe Encephalocele Associated Epilepsy: A Pictorial Review. Clinical Radiology 2025, 87: 106980. DOI: 10.1016/j.crad.2025.106980.Peer-Reviewed Original ResearchTemporal lobe encephalocelePictorial reviewCerebrospinal fluidIdiopathic intracranial hypertensionEpilepsy patientsHerniation of brain tissueElevated intracranial pressureSurgically treatable conditionsMiddle cranial fossaIntracranial hypertensionCranial fossaUnusual locationIntracranial pressureTreatable conditionAssociated with conditionsCT imagesImaging appearanceEpilepsyPatientsBrain tissueDiagnosisImage featuresConsensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal Metastases
Butensky S, Bansal V, Su D, Waheed M, Nikiforchin A, Gomez-Mayorga J, Olecki E, Radomski S, Sun B, Turaga K, Gunderson C, Lacy J, Badgwell B, In H, Kennedy T, Yoon H, Greer J, Sundar R, Woo Y. Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal Metastases. Annals Of Surgical Oncology 2025, 1-18. PMID: 40560499, DOI: 10.1245/s10434-025-17361-2.Peer-Reviewed Original ResearchSynchronous peritoneal metastasesCytoreductive surgeryPeritoneal metastasisConsensus guidelinesLow peritoneal carcinomatosis indexPeritoneal carcinomatosis indexManagement of gastric cancerMultidisciplinary preoperative assessmentLimited treatment optionsNon-surgical managementLevel of evidenceClinical management pathwaysDiagnostic laparoscopyRandomized controlled trialsSystemic therapySurvival benefitPreoperative assessmentDisease subsetsTreatment optionsClinical trialsGastric cancerPathway blockBurden of diseasePatientsBackgroundGastric cancerPatient Volume Requirements: Evaluation of the 2025 ACGME Proposal for Emergency Medicine Residency Programs
Topping C, Rothenberg C, Gettel C, Sangal R, Goldflam K, Ulrich A, Agrawal P, Courtney D, Venkatesh A. Patient Volume Requirements: Evaluation of the 2025 ACGME Proposal for Emergency Medicine Residency Programs. AEM Education And Training 2025, 9: e70071. PMID: 40574930, PMCID: PMC12189752, DOI: 10.1002/aet2.70071.Peer-Reviewed Original ResearchPatient volumeRural-Urban Commuting Area codesAmerican Hospital Association Annual SurveyHospital's zip codeMedian volumeEM residency programsVolume thresholdCross-sectional analysisEM residentsArea codeRural programsACGME websiteEM programsClinical exposureResidency programsProgram lengthACGMERural-urbanAnnual surveyResidentsUrban programsProgram informationPatientsProgramYearsLong-term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.
Levy C, Trivedi P, Kowdley K, Gordon S, Bowlus C, Londoño M, Hirschfield G, Gulamhusein A, Lawitz E, Vierling J, Mayo M, Jacobson I, Kremer A, Corpechot C, Jones D, Buggisch P, Zhuo S, Proehl S, Heusner C, McWherter C, Crittenden D. Long-term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. The American Journal Of Gastroenterology 2025 PMID: 40553148, DOI: 10.14309/ajg.0000000000003603.Peer-Reviewed Original ResearchPrimary biliary cholangitisMonths of treatmentNumerical rating scaleLong-term efficacyBiliary cholangitisResponse ratePruritus Numerical Rating ScaleSerious adverse eventsYear of treatmentInterim study resultsComposite response rateInterim cutoffLong-term useOpen-labelPlacebo-controlledPlacebo-treatedTrial patientsAdverse eventsSeladelparPatientsResponse completenessAssurance studyCholangitisMonthsRating ScaleGenetics of Growth Hormone Deficiency: Insights from a Cohort of 203 Patients
Ribeiro A, Coutinho E, Syed N, Bastos M, Bacelar C, Costa C, Freitas P, Gomes L, Agapito A, Fonseca F, Amaral D, Carvalho D, Sampaio M, Pereira B, Antunes A, Leite V, Castro J, Barros L, Pina R, Martins S, Martinho M, Martins D, Luiz H, Mirante A, Lopes L, Limbert C, Pereira C, Gomes M, Cardoso H, Dinis I, Paiva S, Gonçalves C, Saraiva L, Lemos M. Genetics of Growth Hormone Deficiency: Insights from a Cohort of 203 Patients. The Journal Of Clinical Endocrinology & Metabolism 2025, dgaf377. PMID: 40554621, DOI: 10.1210/clinem/dgaf377.Peer-Reviewed Original ResearchVariants of Uncertain SignificanceGH deficiencyWhole-exome sequencingGrowth hormoneGH-deficient patientsSevere short statureProportion of patientsHypothalamic-pituitary developmentMulticentre cohortDigenic mutationsShort statureGenetic spectrumExome sequencingPortuguese cohortRecurrent mutationsNF1 genePatientsGenetic architectureGenetic mutationsGenetic causeSanger sequencingGenetic heterogeneityGenetic basisCohortCausative factorsDiagnosis and management of cardiogenic shock.
Bellumkonda L. Diagnosis and management of cardiogenic shock. Current Opinion In Critical Care 2025 PMID: 40552838, DOI: 10.1097/mcc.0000000000001288.Peer-Reviewed Original ResearchCardiogenic shockLong-term outcomes of patientsOutcomes of patientsMultidisciplinary team-based approachLong-term outcomesManagement of cardiogenic shockAcute myocardial infarctionOverall prognosisStages of shockInfluence prognosisAggressive managementPoor prognosisRisk stratificationImprove mortalityTreatment strategiesTeam-based approachPhenotypic presentationMyocardial infarctionPrognosisClinical practiceEscalate careDisease processEarly identificationRefining interventionsPatientsPre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis
Caines A, Lu M, Wu T, Trudeau S, Melkonian C, Gonzalez H, Sahota A, Schmidt M, Daida Y, Bowlus C, Gordon S. Pre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis. Journal Of Gastroenterology And Hepatology 2025 PMID: 40551359, DOI: 10.1111/jgh.17035.Peer-Reviewed Original ResearchPrimary biliary cholangitisAntimitochondrial antibody positivityAntimitochondrial antibodiesYears prior to diagnosisAMA-positiveNHW patientsBiliary cholangitisDiagnosis of primary biliary cholangitisBlack patientsPrimary biliary cholangitis patientsAlkaline phosphatasePositive antimitochondrial antibodyElevated alkaline phosphataseEvaluate racial differencesPre-diagnosisAsian American Pacific IslanderPBC patientsAAPI patientsPatient groupALP levelsPatientsDiagnosisNHWCholangitisNon-HispanicP232 Long-term safety of seladelpar 10 mg with up to 5 years of treatment in patients with primary biliary cholangitis
Trivedi P, Gordon S, Gulamhusein A, Villamil A, Lawitz E, Vierling J, Londoño M, Kremer A, Bowlus C, Proehl S, Zhuo S, Crittenden D, McWherter C. P232 Long-term safety of seladelpar 10 mg with up to 5 years of treatment in patients with primary biliary cholangitis. 2025, a228-a228. DOI: 10.1136/gutjnl-2025-bsg.366.Peer-Reviewed Original ResearchMedications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom.
Im G, Asgharpour A, Aby E, Stine J, Mellinger J, Luther J, Izzy M, Haque L, Lee B, Cotter T, Sherman C, Jophlin L, Goel A, Rice J, Chandna S, Lizaola-Mayo B, Chen P, Singal A, Bansal M. Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom. Journal Of Clinical Gastroenterology 2025 PMID: 40549581, DOI: 10.1097/mcg.0000000000002147.Peer-Reviewed Original ResearchWeight loss medicationsGlucagon-like peptide-1Weight lossGastroenterology providersGlucagon-like peptide-1 receptor agonistsPrescribed off-label medicationsPrescribing weight loss medicationsOff-label medicationsFDA-approved medicationsLiver transplant centersOff-label prescribingMedication prescription ratesReceptor agonistsCost/insurance coveragePrescription ratesLiver diseaseSide effectsTransplant centersPeptide-1Steatotic liver diseaseObesity educationBenefit patientsPatientsResmetiromMedicationLetter re: CT vs MRI C-Spine Imaging for C-Spine Clearance in Obtunded Patients in Low-Energy Trauma Mechanisms.
Malhotra A, Wu X. Letter re: CT vs MRI C-Spine Imaging for C-Spine Clearance in Obtunded Patients in Low-Energy Trauma Mechanisms. The American Surgeon 2025, 31348251353799. PMID: 40555398, DOI: 10.1177/00031348251353799.Peer-Reviewed Original ResearchPart II. Dermatologic Manifestations Associated with Treatment of Patients with Kidney Disease
Singal A, Cowper S, Ko C, Kroshinsky D, Lipner H, Robinson-Bostom L, Yosipovitch G, Lipner S. Part II. Dermatologic Manifestations Associated with Treatment of Patients with Kidney Disease. Journal Of The American Academy Of Dermatology 2025 PMID: 40543663, DOI: 10.1016/j.jaad.2025.06.034.Peer-Reviewed Original ResearchEnd stage kidney diseaseKidney diseaseMultidisciplinary team-based approachTreatment of patientsNephrogenic systemic fibrosisStage kidney diseaseClinical presentationSteal syndromeAffected patientsDermatological manifestationsSystemic fibrosisPatientsDialysis-related amyloidosisTeam-based approachUnique treatmentDiseaseCalciphylaxisFibrosisSyndromeDermatosesDermatologistsKidneyAmyloidosisPart I. Dermatologic Manifestations in Patients with Kidney Disease
Singal A, Liu J, Cowper S, Ko C, Kroshinsky D, Lipner H, Robinson-Bostom L, Yosipovitch G, Lipner S. Part I. Dermatologic Manifestations in Patients with Kidney Disease. Journal Of The American Academy Of Dermatology 2025 PMID: 40543664, DOI: 10.1016/j.jaad.2025.06.035.Peer-Reviewed Original ResearchChronic kidney diseaseChronic kidney disease patientsDermatological manifestationsKidney diseaseLack of consensus guidelinesAvoidance of complicationsCKD-associated pruritusPorphyria cutanea tardaUremic frostHistopathological presentationPrompt recognitionConsensus guidelinesPigmentary changesDifferential diagnosisPerforating disordersNail changesCutanea tardaDermatological diseasesPatientsUnique dermatosisDiseaseManifestationsComplicationsPruritusDermatosesUnderstanding Racial and Ethnic Disparities in Myasthenia Gravis Outcomes
McLaren N, Roy B, Nowak R. Understanding Racial and Ethnic Disparities in Myasthenia Gravis Outcomes. Neurology Clinical Practice 2025, 15: e200503. PMID: 40584640, PMCID: PMC12204767, DOI: 10.1212/cpj.0000000000200503.Peer-Reviewed Original ResearchLong-term outcomes of patientsOutcomes of patientsLong-term outcomesAA patientsNon-Hispanic patientsMyasthenia gravisWhite patientsHistory of thymomaLong-term outcome analysisRetrospective cohort studyYears of follow-up dataDiagnosis of MGRepetitive nerve stimulationFollow-up dataSingle-fiber electromyographyMG crisisClinical featuresClinical profileLogistic regression modelsEthnic differencesAntibody seropositivityCohort studyNerve stimulationOutcome analysisPatientsContraceptive Selection for the Endocrine Patient: What an Endocrinologist Should Know
Zaman A, Lazorwitz A, Wierman M. Contraceptive Selection for the Endocrine Patient: What an Endocrinologist Should Know. Endocrine Reviews 2025, bnaf016. PMID: 40519043, DOI: 10.1210/endrev/bnaf016.Peer-Reviewed Original ResearchContraceptive methodsPregnancy preventionSex steroid replacementHormonal contraceptive methodsHypothalamic-pituitary-gonadal axisBirth control optionsAndrogen suppressionRegular mensesSteroid replacementContraceptive optionsContraceptive usageContraceptive selectionEndocrine patientsEndocrine disordersMetabolic disordersContraceptionEndocrinologistsClinical practiceExogenous hormonesPregnancyPatientsHistory of contraceptionHormoneComprehensive careMedical providersGENE COPY NUMBER ALTERATIONS IDENTIFY SUBSET OF SEZARY SYNDROME PATIENTS WITH WORSE SURVIVAL OUTCOMES
Kiwan A, Foss F, Girardi M, Xu M, Siddon A, Sethi T. GENE COPY NUMBER ALTERATIONS IDENTIFY SUBSET OF SEZARY SYNDROME PATIENTS WITH WORSE SURVIVAL OUTCOMES. Hematological Oncology 2025, 43 DOI: 10.1002/hon.70094_382.Peer-Reviewed Original ResearchEfficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
Savona M, Odenike O, Roboz G, Amin H, DeZern A, Griffiths E, Dao K, Zeidan A, Bhatnagar B, Buckstein R, Leber B, Keating M, Ball S, Oganesian A, Sano Y, Keer H, Garcia‐Manero G. Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies. British Journal Of Haematology 2025 PMID: 40524338, DOI: 10.1111/bjh.20203.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaCMML-specific prognostic scoring systemTreating chronic myelomonocytic leukemiaRed blood cell transfusionTransformation-free survivalPrognostic Scoring SystemBlood cell transfusionHigh-risk diseasePotential prognostic factorsAssociated with survivalDNA methyltransferase inhibitorTransfusion independenceIntermediate-2Median survivalCell transfusionMyelodysplastic syndromePrognostic factorsMyelomonocytic leukemiaSafety profileProspective studyDecitabine/cedazuridineMethyltransferase inhibitorRandomised trialsPatientsResponse rateOutcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16‐Negative Oropharyngeal Cancers
Zakeri K, Wren S, Shang T, Yu Y, Chen L, Shamseddine A, Safavi A, Kang J, Tsai C, Sherman E, Wong R, McBride S, Gelblum D, Riaz N, Lee N. Outcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16‐Negative Oropharyngeal Cancers. Head & Neck 2025 PMID: 40515499, DOI: 10.1002/hed.28217.Peer-Reviewed Original ResearchP16-negative oropharyngeal cancerNodal recurrenceLocoregional recurrenceP16-negativeDistant recurrenceOropharyngeal cancerHead and neck cancer patientsRadiation doseDecrease treatment toxicityNeck cancer patientsPrimary outcome measureConcurrent chemoradiationRadiotherapy doseMedian followConsecutive patientsTreatment toxicityImprove quality of lifeConsecutive cohortCancer patientsRecurrenceQuality of lifeHypopharyngealDosePatientsOutcome measuresProteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure
Hubbell K, Rao V, Scherzer R, Shlipak M, Ivery‐Miranda J, Bansal N, Cox Z, Testani J, Estrella M. Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure. ESC Heart Failure 2025 PMID: 40504107, DOI: 10.1002/ehf2.15342.Peer-Reviewed Original ResearchAcute decompensated heart failureDecompensated heart failureDiuretic responseHeart failureHF rehospitalizationRisk of HF rehospitalizationBiomarker modelAssociated with poor outcomesAssociated with decreased riskAssociated with increased riskAssociated with cardiometabolic diseasesAssociated with mortalityAssociated with rehospitalizationDiuretic resistanceMedian ageResistance cohortClinical factorsPoor outcomeSociodemographic/lifestyle factorsPrognostic toolCombined biomarkersCardiometabolic diseasesPatientsAmbulatory settingMortality riskSustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study
Bernstein J, Betschel S, Busse P, Banerji A, Wedner H, Manning M, Zaragoza-Urdaz R, Anderson J, Gagnon R, Baptist A, Soteres D, Lumry W, Craig T, Petroni D, Hsu F, Nova Estepan D, Juethner S, Watt M, Khutoryansky N, Zuraw B. Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study. Advances In Therapy 2025, 1-20. DOI: 10.1007/s12325-025-03226-3.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsLong-term prophylaxisHereditary angioedemaHAE attack ratesPost-baseline safety assessmentProphylaxis of hereditary angioedemaConclusionReal-world dataInjection site reactionsAttack rateReal-world studyYears of ageFemale patientsLanadelumabSite reactionsAdverse eventsFollow-upSafety signalsSafety dataEMPOWER studyPatientsDeficiency typeAngioedemaLow attack rateSustained effectPost-baselineSafety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)
Gambardella V, Accordino M, Bedard P, Cervantes A, Hamilton E, Italiano A, Kalinsky K, Krop I, Oliveira M, Saura C, Schmid P, Turner N, Varga A, Fernandez-Saranillo A, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman J, Juric D, Jhaveri K. Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374). ESMO Open 2025, 10: 105303. PMID: 40513140, PMCID: PMC12205636, DOI: 10.1016/j.esmoop.2025.105303.Peer-Reviewed Original ResearchHER2-negative advanced breast cancerAdvanced breast cancerAdverse eventsCombination therapyPIK3CA-mutationsBreast cancerHormone receptor (HR)-positiveDiscontinued study treatmentBreast cancer therapyLong-term toleranceDose reductions/interruptionsAny-gradeData cutoffDose modificationTolerability profileHR-positiveProgressive diseaseStudy treatmentMetformin treatmentCancer therapyNo treatmentPatientsRisk factorsTherapyHyperglycemia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply